Dfn-15
Colorectal Adenoma
University of Alabama at BirminghamPhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 41/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Colorectal Adenoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
UMBELLATINE Jing-yuan Fang, MD, Ph. D | Phase 2/3 | B |
Mesalamine UMC Utrecht | Phase 2 | B |
Linaclotide Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 | CCC |
Acetylsalicylic Acid University of Edinburgh | Phase 2 | CCC |
muc1 peptide-poly-iclc vaccine National Cancer Institute (NCI) | Phase 2 | CCC |
View all 11 →
Same molecule, other indications
Dfn-15 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →